Canada Adult Malignant Glioma Therapeutics Market Analysis

Canada Adult Malignant Glioma Therapeutics Market Executive Summary

The Canada Adult Glioma Therapeutics Market is valued at around $176 Mn in 2022 and is projected to reach $348 Mn by 2030, exhibiting a CAGR of 8.9% during the forecast period.

Malignant glioma is a particular kind of malignancy in the brain that develops from glial cells in the central nervous system (CNS). Glial cells are supporting cells in the CNS that can grow into tumours called gliomas. Malignant gliomas are distinguished by their aggressive and invasive nature. Anaplastic astrocytoma, anaplastic oligodendroglioma, and glioblastoma multiforme (GBM) are the three most prevalent forms of malignant gliomas in adults. Typically, a mix of radiation therapy, chemotherapy, and surgery is used for the treatment of malignant gliomas. Because malignant gliomas are aggressive, the prognosis is frequently guarded, and the patient's age, the size and location of the tumour, and the tumour’s response to therapy all affect the patient's chance of survival.

In Canada, the age-standardized prevalence for those aged 20 and above is 7.6 to 8.4 per 100,000. This corresponds to between 6,000 and 6,700 people in the nation who are affected by the illness. Adults are the primary targets of glioma; those between the ages of 45 and 75 have the highest incidence and prevalence of the disease, with GBM accounting for over 60% of cases.

The growth of the Canada Adult Malignant Glioma Therapeutics Market is being driven by increased research and development funding, significant government investments in cancer research, owing to the increased prevalence of brain cancers, the presence of unmet healthcare needs, and a favourable regulatory environment that allows for the rapid approval of innovative medicines.

Key players in the Canada Adult Malignant Glioma Therapeutics Market include Roche, Merck & Co., Pfizer, Amgen, Arbor Pharmaceuticals, Karyopharm Therapeutics, and Azurity Pharmaceuticals. Medicago Inc., CogniMed Therapeutics Inc., and others.

Market Dynamics

Market Growth Drivers

Several market growth drivers regulate the Canada Adult Malignant Glioma Therapeutics Market. Growth in the market for malignant gliomas may result from increased financing for research and development in the healthcare industry, which may pave the way for the development of novel medicines and treatments. The substantial investment made in cancer research by the Canadian government is an illustration of increased spending on research and development. For example, since 2016, the Government of Canada and the Canadian Cancer Society have combined to contribute nearly $40 million to brain cancer research. Pharmaceutical investments and market expansion are drawn to the development of personalized medical techniques, targeted medicines, gene therapy, and immunotherapy because they promise better patient outcomes and longer lifespans. The creation of novel therapies like tumour-treating fields (TT fields), which have demonstrated encouraging outcomes in the treatment of glioblastoma, is an example of how technological breakthroughs in glioma therapy are being applied.

The simple and rapid regulatory clearance procedure is another industry driver. A favourable regulatory environment can promote the research and implementation of innovative medicines for malignant gliomas, ultimately boosting market expansion. Health Canada has put in place mechanisms to expedite the approval of breakthrough medicines, which may assist with novel treatments entering the market. Global glioma treatment market developments and achievements might encourage adaptation and acceptance in Canada, resulting in market growth.

Market Restraints

Some of the key market restraints that may impact the growth of the adult malignant glioma therapeutics market in Canada include the treatment costs, affordability of patients, healthcare burden, and limited acceptance of novel treatments by the general population. Glioma treatment, which includes surgery, radiation, chemotherapy, and targeted medicines, is notably expensive. These expenses can place enormous financial strain on patients and families, thereby restricting access to care and market reach. Temozolomide, a commonly used GBM chemotherapy medication, can cost tens of thousands of dollars every treatment cycle, putting a burden on healthcare resources and individual affordability.

Despite advances, effective treatments for glioma, particularly GBM, remain limited. The disease's aggressiveness and poor prognosis provide hurdles for therapeutic development, resulting in a smaller market reach. While targeted medicines provide hope for individuals with specific mutations, they only assist a subset of patients, limiting their commercial potential in comparison to medications with broader applications.

Notable Recent Updates

June 2023: Health Canada approved Optune for the treatment of newly diagnosed high-grade glioma with unmethylated MGMT promoter status. This expanded access to Optune for a larger patient population, increasing market reach and treatment options.(Source: Health Canada)

October 2023: Roche submitted a new drug application to Health Canada for atezolizumab (Tecentriq), an immunotherapy drug, in combination with temozolomide for newly diagnosed GBM. This potential new treatment option could open doors for future regulatory approvals.

November 2023: The Canadian Cancer Society announced a $4 million grant to support a research project focusing on improving targeted therapies for glioma based on genetic profiling.

Healthcare Policies and Regulatory Landscape

Canadian Medicare is a decentralized, universal, publicly funded healthcare system in Canada. It is largely funded and operated by the country's 13 provinces and territories, with each having its own insurance plan and receiving federal government monetary aid on a per-capita basis. Medically essential hospital and physician services are covered by provincial and territory health insurance policies without direct costs at the moment of treatment. These programs are funded by the provincial and territorial governments with federal funds and Medicaid help. Health Canada is Canada's pharmaceutical regulation agency. It is in charge of examining and allowing pharmaceuticals to be promoted or sold in Canada, as mandated by the Food and Drugs Act (FDA) and its associated regulations (FDR). Health Canada conducts a comprehensive assessment and approval procedure before releasing new treatments. Before a medicine may be disseminated or sold in Canada, its producer must first get a Notice of Compliance (NOC) from Health Canada, and the drug must be issued a Medicine Identification Number (DIN), which uniquely identifies all drug products marketed in a dosage form in the country. Authorities conduct a thorough assessment, and after the treatment is authorized, there are further protocols and rules to follow and take into account before the drug is legally promoted, distributed, and sold in Canada.

Competitive Landscape

Key Players

• Roche
• Merck & Co.
• Pfizer
• Amgen
• Arbor Pharmaceuticals
• Karyopharm Therapeutics
• Azurity Pharmaceuticals
• Medicago Inc.
• CogniMed Therapeutics, Inc